Stockscreener 앱 받기
1.52
2.29%
-0.01
전일 마감가:
$1.53
열려 있는:
$1.48
하루 거래량:
324.50K
Relative Volume:
0.12
시가총액:
$293.70M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-5.4286
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
+1.70%
1개월 성능:
-4.78%
6개월 성능:
+31.14%
1년 성능:
-18.75%
1일 변동 폭
$1.48
$1.54
1주일 범위
$1.41
$1.56
52주 변동 폭
$1.03
$2.565
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
1.515 | 293.70M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.65 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.62 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.89 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.52 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.68 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
ATAI Life Sciences N.V [ATAI] stock for 65,560 USD was sold by Kirpekar Sahil - knoxdaily.com
Investing in ATAI Life Sciences N.V (ATAI) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating - Seeking Alpha
At What Point In Time Would I Choose To Purchase ATAI Life Sciences N.V (NASDAQ: ATAI) Stock? - stocksregister.com
Psychedelic Drugs Market Future Business Opportunities - openPR.com
Berenberg starts atai Life Sciences coverage with Positive rating By Investing.com - Investing.com Australia
Berenberg starts atai Life Sciences coverage with Positive rating - Investing.com
Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds? - Insider Monkey
How Are Things Looking For ATAI Life Sciences N.V (NASDAQ: ATAI) For The Short Term? - stocksregister.com
Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares - Investing.com UK
Atai Life Sciences CEO Rao Srinivas sells $101,814 in common shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief scientific officer sells $17,767 in shares By Investing.com - Investing.com South Africa
Atai life sciences CMO Craig James sells $15,610 in shares By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock By Investing.com - Investing.com South Africa
Atai Life Sciences chief business officer sells $65,560 in stock - Investing.com India
Atai Life Sciences chief scientific officer sells $17,767 in shares - Investing.com India
Atai Life Sciences CFO sells shares worth $45,285 - Investing.com India
Atai life sciences CMO Craig James sells $15,610 in shares - Investing.com India
Atai Life Sciences director Angermayer buys $2.52 million in shares By Investing.com - Investing.com UK
Atai Life Sciences director Angermayer buys $2.52 million in shares - Investing.com
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy - Cryptonews
ATAI Life Sciences invests $5M in Bitcoin as reserve asset By Investing.com - Investing.com Australia
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial - TipRanks
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Yahoo Finance
Is Atai Life Sciences N.V. (ATAI) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
How is ATAI’s stock performing after recent trades? - US Post News
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
ATAI’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Atai: Following The Path That Spravato Laid And Moving Beyond It - Seeking Alpha
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference - Yahoo Finance UK
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Atai Life Sciences Raises $63.3 Million After Closing Public Offering -February 20, 2025 at 10:10 am EST - Marketscreener.com
atai Life Sciences completes public offering, raising $63.25M - Proactive Investors UK
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares - Yahoo Finance UK
Apeiron Investment Group purchases $22.8m in ATAI Life Sciences shares By Investing.com - Investing.com Australia
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
atai Life Sciences announces pricing of $55M public offering of shares - Proactive Investors UK
Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):